Mannin Research, Inc.

Company's Liver Cancer Drug Candidate IP Portfolio strengthened Company provides operational update on strategic opportunities NEW YORK, April 14, 2023 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, asset Uttroside B – has received a patent in the United States and a notice of allowance in Europe, adding to the already issued patents in Korea, Canada and Japan. In addition, recent results from pre-clinical pharmacokinetic testing have been very encouraging and the data supports advancing the program. Uttroside B shows tremendous value in the Liver Cancer Market and has received Orphan Drug designation from the FDA. The America Cancer Society () reported in this year alone, an estimated 42,000 adults in the United States will be diagnosed with primary liver cancer. It is also estimated that 30,000 deaths from this disease will occur this year. The 5-year survival rate is 20%, compared to just 3% 40 years ago. For the 44% of people who are diagnosed with liver cancer at an early stage, the 5-year survival rate is 34%. There is significant demand for better therapeutic alternatives in the space. Q BioMed has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology, an Autonomous Institute under the Department of Biotechnology, Government of India, and the Oklahoma Medical Research Foundation. In addition to successfully prosecuting its IP portfolio the company is engaged in finding strategic opportunities to best preserve and create value for its shareholders. Denis Corin, QBioMed Inc. CEO said, "We believe in the inherent value we have created in our pipeline. With the assistance of bankers and funding partners we are evaluating strategic opportunities including financing, mergers, and asset joint ventures or sale of assets in order to maximize value for our shareholders in a very difficult market." The company has an approved non-opioid cancer pain palliation asset that is an effective therapeutic, it's a non-opiate and can save hospitals millions of dollars in economic outcome improvements. In addition, it has a very promising liver cancer chemotherapeutic that has been granted US orphan drug status and several international patents, and recently was also granted a patent in USA. The plan is to advance this asset into the clinic in a non-US country where the government is offering 43% cash rebate and combined with US dollar strength would allow us to complete that clinical phase for 50% of the typical cost and potentially in a shorter timeframe. It previously reported the remarkable potency of Uttroside-B against liver cancer cells and believes it could be a very valuable drug candidate in the liver cancer market which has few therapeutics for a growing patient population. QBioMed has an equity stake in Mannin Research valued at approximately $3.5M USD. This asset value is expected to rise significantly as they advance their programs assisted by non-dilutive government funding already amounting to over $15M and which could exceed $100M over the next year. Data from the Mannin planned ARDS trial will support the filings for further indications, including kidney disease and glaucoma. Combined, the addressable market for these therapies is over $150 billion a year. The company believes these assets are far more valuable than the current market cap of the company and are determined to find a way to recognize that value for its shareholders and those that made these assets into promising therapeutics that could help many people around the world. While the company believes these corporate activities are building value, it is of course aware of the dismal stock performance. Unfortunately, its cap and debt structure coupled with the general macro-market uncertainty and specifically the biotech market capitulation, has resulted in a valuation for QBIO that they maintain, is not reflective of the inherent asset value within their portfolio. The current microcap and biotech funding climate is making raising capital very challenging and keeping up with the considerable expense of public company operations and professional fees has resulted in them not being able to timely file or annual report. The company is working on remedying that as soon as possible About Q BioMed Inc. Q BioMed Inc is a biotech acceleration and commercial stage company. Q BioMed is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need‏. Please visit and sign up for regular updates. Forward-Looking Statements: This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Q BioMed Media Contact: Denis Corin CEO Investor Relations - Landon Capital: Keith Pinder +1(404) 995-6671 [email protected] SOURCE Q BioMed Inc.

Company converts future royalty into 15% equity in multi-billion dollar potential product portfolio with additional $20M royalty NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Q BioMed Inc. (QBIO), Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that it has converted its long-term royalty agreement into an equity stake in Mannin Research Inc. (MRI), a private Canadian controlled biotechnology company, based in Toronto, Ontario, Canada. The conversion results in two key outcomes: QBIO receives a 15% equity stake in the form of common shares in MRI at a current valuation of MRI at CAD$30 million, and a royalty payment of $20 million on realization of future net sales. QBIO expects the value of its investment to increase, due to quantifiable near-term and medium-term catalysts, including the signing of commercialization agreements by MRI, and completion of clinical milestones as part of its drug development program. In addition, utilizing MRI's internal pro-forma revenue projections for 2023 & 2024 and comparable market transactions, MRI's drug development pipeline and companion diagnostics, are estimated to achieve a net present value close to the billion-dollar mark as it moves from its near-term clinical milestones to commercial revenues. To support its critical path to commercial success, MRI has already accessed over CAD$30M in non-dilutive capital from government funding sources with significantly more expected over the next 18 months. This funding has greatly de-risked the earlier stages of development, providing an accelerated path to market, and enabling the completion of technical milestones that in turn support the achievement of commercial milestones. This dependable cycle of investment and de-risking has added significant value to QBIO's investment. Lastly, QBIO's only obligation to contribute to future R&D expenditures in this platform totals USD$1.5million. MRI's drug development pipeline is positioned to be a multi-billion dollar blockbuster franchise for years to come. The pipeline includes two therapeutic modalities: large molecule (recombinant protein therapeutic) and small molecule drugs. The MRI pipeline addresses the unmet needs for patients in three initial indications: glaucoma, kidney disease, and ARDS. The common thread for all three diseases is the treatment of an underlying vascular dysfunction that can be ameliorated by targeting the Ang1-Tie2 mechanism of action. In a context dependent manner, MRI has developed a series of drugs, as well as companion diagnostics for glaucoma and ARDS, respectively, to address the unmet needs of these patients. Denis Corin, QBioMed CEO says, "The value of our investment into the Mannin pipeline to date is not recognized at all on our balance sheet. The conversion of our agreement to this value-based equity ownership allows us to immediately recognize approximately CAD$5.0 million in shareholder equity and we anticipate this value to grow substantially over the next 12 months. Our investment has contributed to the development of a blockbuster franchise of drugs and companion diagnostics addressing millions of patients with significant unmet needs. We expect this to translate into a very significant return on our investment capital." He continued, "Mannin has a portfolio of drugs that has a total addressable market of over $150 billion per year. Multiple large pharma companies have indicated interest in bringing the Mannin drugs to patients in markets around the world. We expect that at least one major strategic deal will be announced by Q1 of 2023 and additional transformative economic transactions later in 2023, further validating the MRI drug pipeline and its blockbuster potential. These would be very significant value creating events for both QBIO and Mannin shareholders. QBIO is so proud to have been an integral part of this development from the beginning." Dr. George N. Nikopoulos, President & CEO Mannin Research Inc., "Our team at Mannin has believed in our technology platform from the early days with Dr. Susan Quaggin's leadership as our founding CSO. Transition to today's news and our new incoming CSO from big pharma, new and experienced management team, and a board of directors with years of experience in bringing drugs to market, Mannin has been able to bring together a best-in-class team," said Dr. Nikopoulos. He continued, "Together we believe our first-in-class group of therapeutics will make a real difference in the lives of patients suffering from ARDS, glaucoma, and kidney disease, which is really why we do what we do. We were proud to partner with QBIO from the start and are grateful for their investment in us and what they have contributed to our progress. We are equally happy to complete this conversion so that we can better communicate the value that QBIO has in Mannin and its future success." About Q BioMed Inc. Q BioMed aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets. For more information please visit . About Mannin Research Inc. Mannin Research Inc. is a Canadian private biotechnology company, headquartered in Toronto, Ontario. It conducts research and development on innovative new drugs, therapeutics, and diagnostics. The company mission is to drive innovation in life sciences to make a difference in healthcare globally. For more information please visit Forward-Looking Statements: This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Contact: Q BioMed Media Contact: Denis Corin CEO Investor Relations: Keith Pinder +1(404) 995-6671 [email protected] SOURCE Q BioMed Inc.

Company converts future royalty into 15% equity in multi-billion dollar potential product portfolio with additional $20M royalty NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Q BioMed Inc. (QBIO), Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that it has converted its long-term royalty agreement into an equity stake in Mannin Research Inc. (MRI), a private Canadian controlled biotechnology company, based in Toronto, Ontario, Canada. The conversion results in two key outcomes: QBIO receives a 15% equity stake in the form of common shares in MRI at a current valuation of MRI at CAD$30 million, and a royalty payment of $20 million on realization of future net sales. QBIO expects the value of its investment to increase, due to quantifiable near-term and medium-term catalysts, including the signing of commercialization agreements by MRI, and completion of clinical milestones as part of its drug development program. In addition, utilizing MRI's internal pro-forma revenue projections for 2023 & 2024 and comparable market transactions, MRI's drug development pipeline and companion diagnostics, are estimated to achieve a net present value close to the billion-dollar mark as it moves from its near-term clinical milestones to commercial revenues. To support its critical path to commercial success, MRI has already accessed over CAD$30M in non-dilutive capital from government funding sources with significantly more expected over the next 18 months. This funding has greatly de-risked the earlier stages of development, providing an accelerated path to market, and enabling the completion of technical milestones that in turn support the achievement of commercial milestones. This dependable cycle of investment and de-risking has added significant value to QBIO's investment. Lastly, QBIO's only obligation to contribute to future R&D expenditures in this platform totals USD$1.5million. MRI's drug development pipeline is positioned to be a multi-billion dollar blockbuster franchise for years to come. The pipeline includes two therapeutic modalities: large molecule (recombinant protein therapeutic) and small molecule drugs. The MRI pipeline addresses the unmet needs for patients in three initial indications: glaucoma, kidney disease, and ARDS. The common thread for all three diseases is the treatment of an underlying vascular dysfunction that can be ameliorated by targeting the Ang1-Tie2 mechanism of action. In a context dependent manner, MRI has developed a series of drugs, as well as companion diagnostics for glaucoma and ARDS, respectively, to address the unmet needs of these patients. Denis Corin, QBioMed CEO says, "The value of our investment into the Mannin pipeline to date is not recognized at all on our balance sheet. The conversion of our agreement to this value-based equity ownership allows us to immediately recognize approximately CAD$5.0 million in shareholder equity and we anticipate this value to grow substantially over the next 12 months. Our investment has contributed to the development of a blockbuster franchise of drugs and companion diagnostics addressing millions of patients with significant unmet needs. We expect this to translate into a very significant return on our investment capital." He continued, "Mannin has a portfolio of drugs that has a total addressable market of over $150 billion per year. Multiple large pharma companies have indicated interest in bringing the Mannin drugs to patients in markets around the world. We expect that at least one major strategic deal will be announced by Q1 of 2023 and additional transformative economic transactions later in 2023, further validating the MRI drug pipeline and its blockbuster potential. These would be very significant value creating events for both QBIO and Mannin shareholders. QBIO is so proud to have been an integral part of this development from the beginning." Dr. George N. Nikopoulos, President & CEO Mannin Research Inc., "Our team at Mannin has believed in our technology platform from the early days with Dr. Susan Quaggin's leadership as our founding CSO. Transition to today's news and our new incoming CSO from big pharma, new and experienced management team, and a board of directors with years of experience in bringing drugs to market, Mannin has been able to bring together a best-in-class team," said Dr. Nikopoulos. He continued, "Together we believe our first-in-class group of therapeutics will make a real difference in the lives of patients suffering from ARDS, glaucoma, and kidney disease, which is really why we do what we do. We were proud to partner with QBIO from the start and are grateful for their investment in us and what they have contributed to our progress. We are equally happy to complete this conversion so that we can better communicate the value that QBIO has in Mannin and its future success." About Q BioMed Inc. Q BioMed aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets. For more information please visit . About Mannin Research Inc. Mannin Research Inc. is a Canadian private biotechnology company, headquartered in Toronto, Ontario. It conducts research and development on innovative new drugs, therapeutics, and diagnostics. The company mission is to drive innovation in life sciences to make a difference in healthcare globally. For more information please visit Forward-Looking Statements: This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Contact: Q BioMed Media Contact: Denis Corin CEO Investor Relations: Keith Pinder +1(404) 995-6671 ir@qbiomed.com View original content: SOURCE Q BioMed Inc.